Yellowstone Biosciences

Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology.

The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to selectively eliminate cancer cells while sparing healthy tissue.

Yellowstone draws on a proprietary biobank of samples from over 3,000 AML patients assembled over two decades of research at the University of Oxford.